Mode
Text Size
Log in / Sign up
N/A N=73 Treatment

Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases

Pain · Neoplasm Metastasis · Bone Metastasis of Diverse Origins

Enrolled (actual)
73
Serious AEs
4.6%
Results posted
Sep 2019
Primary outcome: Primary: Change From Baseline in Worst Pain Scores as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) at Week 8 — 7.26; -2.61 score on a scale — p=0.0746

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cryoablation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boston Scientific Corporation
Primary completion
Mar 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Worst Pain Scores as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) at Week 8
7.26; -2.61 0.0746

Summary

This study will evaluate the efficacy of cryoablation for palliation of painful metastases in participants with metastatic lesions involving bone who have failed, are not candidates for, or are not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics).

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Metastatic disease involving bone with metastatic disease previously confirmed by prior biopsy; or Metastatic disease involving bone previously confirmed on imaging (for example, computed tomography [CT] or magnetic resonance imaging [MRI]) with known (biopsied) primary disease (primary bone cancer is excluded)
  • Current analgesic therapies have failed, the participant is not a candidate for, or the participant is not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics)
  • The 'worst pain' in the last 24 hours must be reported to be 4 or above on a scale of 0 (no pain) to 10 (pain as bad as participant can imagine)
  • Pain must be from one painful metastatic lesion involving the bone that is amenable to cryoablation with CT (additional less painful metastatic sites may be present)
  • Cryoablation should be performed within 14 days of screening visit
  • If taking hormonal therapy, use should be stable (no changes within 4 weeks prior to the cryoablation procedure)
  • Karnofsky Performance Scale (KPS) score ≥60
  • Life expectancy ≥3 months
  • No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up
  • Known coagulopathy or bleeding disorders are controlled

Exclusion Criteria

  • Primary cancer is leukemia, lymphoma, or myeloma
  • Tumor involves a weight-bearing long bone of the lower extremity with the tumor causing >50% loss of cortical bone
  • Has undergone prior surgery at the tumor site or the index tumor has undergone previous surgery or ablation treatment
  • Prior radiation therapy of the index tumor <3 weeks prior to the screening visit
  • Index tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
  • Anticipated treatment of the index tumor that would require iceball formation within 0.5 centimeters (cm) of the spinal cord, brain, other critical nerve structure, or large abdominal vessel (possibly achieved with additional maneuvers such as hydrodissection)
  • Index tumor involves the skull
  • Currently pregnant, nursing, or wishing to become pregnant during the study
  • Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, or cerebrovascular event within 6 months prior to the screening visit
  • Concurrent participation in other studies that could affect the primary endpoint
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02511678). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search